Evommune (EVMN) EBT (2024 - 2026)

Evommune (EVMN) has reported EBT for 3 consecutive years, with -$113.6 million the latest figure, recorded in Q1 2026.

• In Q1 2026, EBT fell 677.38% year-over-year to -$113.6 million; the TTM figure through Mar 2026 stood at -$175.9 million (changed N/A YoY), while the FY2025 annual figure was -$132.3 million, down 95.72% from the prior year.
• EBT retreated to -$113.6 million in Q1 2026 per EVMN's latest filing, from -$28.2 million in the prior quarter.
• Across five years, EBT topped out at -$14.6 million in Q1 2025 and bottomed at -$113.6 million in Q1 2026.
• Historically, EBT has averaged -$35.4 million across 3 years, with a median of -$20.1 million in 2024.
• Annual changes were most pronounced in 2025 — EBT slipped 21.73% — and 2026, when it plunged 677.38%.
• Evommune's EBT stood at -$20.7 million in 2024, then sank by 36.16% to -$28.2 million in 2025, then plunged by 302.57% to -$113.6 million in 2026.
• Business Quant data shows EVMN's EBT at -$113.6 million in Q1 2026, -$28.2 million in Q4 2025, and -$19.4 million in Q3 2025.